Simpson-Golabi-Behmel syndrome (SGBS) is an X linked disorder characterised by pre-and postnatal overgrowth, coarse facial features, and visceral and skeletal abnormalities. Like other overgrowth syndromes, in the SGBS there is an increased risk for developing neoplasia, mainly embryonic, such as Wilms tumour. We report a 3 year old male patient with SGBS and hepatocellular carcinoma, a previously undescribed tumour associated with the syndrome.
Simpson-Golabi-Behmel syndrome (SGBS, MIM 312870) is an X linked condition characterised by pre-and postnatal overgrowth and by a variety of congenital defects such as multiple midline malformations, cardiac and vertebral anomalies, coarse face, macroglossia, organomegaly, and developmental delay.
In this condition there is a higher than expected incidence of embryonic neoplasia, including Wilms tumour, atypical embryoma, and neuroblastoma. Affected males may also be at risk for developing other embryonal tumours including hepatoblastoma and rhabdomyosarcoma. 1 The primary defect has recently been assigned to a gene mapping on Xq26 which encodes a putative extracellular proteoglycan, glypican-3 (GPC3). Such a proteoglycan is inferred to play an important role in growth control in mesodermal tissues2 and in tumour predisposition.3 Four new GPC3 mutations have recently been identified in nine additional patients. 4 We report on a 3 year old male patient with clinical findings of SGBS and hepatocellular carcinoma. As far as we know this is the first patient with SGBS with a primary epithelial neoplasm of the liver.
Case report
The child was born prematurely (36 weeks) as the second child of young, nonconsanguineous parents. The pregnancy was complicated by polyhydramnios and resulted in delivery by caesarean section. His mother had a coarse face with a broad nasal bridge, epicanthic folds, and abnormal dentition including dental malocclusion and enamel defects. The father was healthy and had no abnormal features. The patient's 7 year old sister was not examined but was reported to be normal with "mild speech difficulties". At birth his weight was 4100 g (97th centile), length was 54 cm (97th centile), and head circumference (OFC) was 34.5 cm (60th centile and Beckwith-Wiedemann syndrome (hepatoblastoma). -' In overgrowth syndromes, serum alphafetoprotein is considered to be an important marker for embryonal cell tumours.'5 Therefore, the association of hepatocellular carcinoma and SGBS, though previously undescribed, might have been expected. In patients with somatic overgrowth, HughesBenzie et al (unpublished data) recommended that embryonal tumours might be routinely screened by serum alphafetoprotein and betahCG measurements plus abdominal ultrasound every four months up to 5 years of age, every six months between 5 and 8 years, and yearly in children older than 8 years. The present patient had not been on a tumour screening programme because he had not been diagnosed as having SGBS until he was referred to our hospital.
Lipomas of the scalp or corpus callosum have not been previously reported in SGBS patients. The significance of these findings is not clear but could be related to the tumour predisposition observed in this type of overgrowth syndrome. Lipomas have been observed in other disorders with overgrowth, such as the Proteus syndrome and the BannayanRuvalcaba-Myhre syndrome.
The phenotype of the proband's mother was also remarkable. She had a coarse face with a broad nasal bridge, epicanthic folds, and abnormal dentition, including dental malocclusion and enamel defects. Manifestations observed in at least one mother in the report of Golabi and Rosen6 probably represent a lyonisation effect and should be looked for in all female relatives of SGBS children. Extreme lyonisation distortion during development can result in a heterozygous female with a phenotype as severe as seen in hemizygotes. This was reported in two females with typical features of SGBS and X;autosome translocations.' 4 Linkage analysis performed in several families mapped the SGBS gene to the long arm of the X chromosome, close to the HPRT locus.'2 20 Pilia et af' have provided strong evidence for GPC3, a member of the glypican related integral membrane proteoglycan family, as a candidate for the SGBS gene. The gene GPC3, which encodes the putative extracellular proteoglycan GPC3, is inferred to play an important role in growth control in embryonal mesodermal tissues. It appears that intact GPC3 would form a complex with insulin-like growth factor 2 (IGF2) sequestering the latter, or could facilitate downregulation and turnover of IGF2 through a further interaction with IGF2 receptor (also known as mannose-6-phosphate receptor, M6P/IGF2R). SGBS could thus result from loss of function mutations that reduce GPC3 binding and thereby increase the active level of IGF2.' From the phenotype of dysplasia-gigantism in SGBS, they speculated that GPC3 would be involved in the suppression/modulation of growth in the predominantly mesodermal tissues and organs that show high levels of GPC3 and would tend to overgrow in its absence.2 Moreover, the similarity in the mutant phenotypes of SGBS patients and Igf2r transgenic mice suggests that glypican-3 and IGF2 receptor function sequentially or as coreceptors for IGF2. In this way, a deficiency of either could result in increased or abnormal IGF2 activity.3 Another possibility is that GPC3 normally facilitates programmed cell death (apoptosis), balancing the role of IGF2 in promoting cell growth. Thus, GPC3 deficiency might lead to overgrowth and tumour predisposition.3 Recently, using Southern blot analysis and PCR amplification of intraexonic sequences, Hughes-Benzie et at' identified four new GPC3 mutations. Deletions were identified throughout the length of the GPC3 transcript with no evidence of mutation hot spots. On the other hand, De Souza et af' have recently shown that 70% of human hepatocellular tumours have loss of heterozygosity at the M6P/IGF2R locus and they have identified point mutations in the remaining allele of 25% of the human hepatocellular carcinomas with loss of heterozygosity, providing evidence that the M6P/IGF2R functions as a tumour suppressor in human liver carcinogenesis." Thus, the interactions between GPC3, M6P/IGF2R, and IGF2 seem to be essential in the pathophysiology of late embryonic development, somatic growth, and carcinogenesis. The observation of SGBS and hepatocellular carcinoma in the patient reported here further supports the interaction of these proteins.
Though there is considerable clinical overlap between SGBS and Beckwith-Wiedemann syndrome (macrosomia, cleft palate, visceromegaly, macroglossia, herniae, neonatal hypoglycaemia, and risk of tumours), which have led to confusion, it is very important to differentiate them because genetic counselling varies, the former being an X linked recessive syndrome and the latter autosomal dominant with imprinting. 23 24 The tumour risk for BWS is 5-10%3 and that for SGBS is as yet undefined, but could be estimated as 10-15%. This tumour development in SGBS has been observed in patients with deletions of the 5' end of the GPC3 gene (table 1).2 4 25 Accurate diagnosis of somatic overgrowth disorders and molecular analysis of DNA samples for the GPC3 gene might be helpful for prenatal diagnosis in SBGS families and for patients with somatic overgrowth and tumours.
We are deeply indebted to Dr Horacio M Ochoa who followed up the child until he was referred to us.
